InSite Vision Announces Publication of Preclinical Data Showing that DuraSite(R)-Enabled Bromfenac Attains Higher Concentrations in Ocular Tissues Compared to the Commercially Available Drug

ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (OTCBB:INSV) today announced the publication of a study entitled “Pharmacokinetic Comparisons of Bromfenac in DuraSite and Xibrom” in the peer-reviewed Journal of Ocular Pharmacology and Therapeutics.